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Introduction
Post-translational modifications (PTMs) of proteins contribute significantly to the functional diversity of the proteome (1) . For example, ubiqutin/proteasome pathway (UPP) plays a critical role in the hypoxic response and tumorigenesis by regulating protein stability of the master transcription factor HIF-1α (2) (3) (4) (5) . Both the UPP and interferon-stimulated gene 15 (ISG15) conjugation (ISGylation) pathways, which are regulated in response to interferon, contribute to inflammatory responses and cancer cell-killing activity of drugs (6) (7) (8) (9) . Notably, hypoxia and inflammation are two microenvironments involved in cancer development (5, (10) (11) (12) .
The initiation and maintenance of tumor cells rely largely on their ability to interact with and adapt to changes in microenvironments (5, 11) . Cells within rapidly growing tissues, whose proliferation rate becomes faster than their angiogenesis rate, such as in embryos and solid tumors, often encounter hypoxic stress. Moreover, hypoxia is also a feature of the microenvironment in chronic inflammatory conditions such as arthritis, inflammatory bowel disease and almost all types of solid tumors encounter hypoxic inflammation (10, 13) . These two interdependent microenvironments thus impact not only the progression of cancer but also its development (12) . However, the potential interaction between cancer-related inflammation and hypoxic environments during tumorigenesis and the underlying crosstalk mechanism remain largely unclear.
Cells respond to hypoxia and inflammation through transcriptional programming, allowing them to adjust to the optimal cellular context (4, 5) . Hypoxia induces expression of a defined set of genes through hypoxia-inducible factors (HIFs, especially HIF-1α) thereby being associated with erythropoiesis, glycolysis, the epithelial-mesenchymal transition (EMT), angiogenesis, tumor metastasis, therapy resistance and a poor prognosis (14) . Several regulatory mechanisms affecting the activity of HIF-1α have been identified: (i) HIF-1α stability is regulated by changes in the oxygen tension. HIF-1α is degraded under normoxia by UPP, which involves prolyl hydroxylase (PHD1/2/3)-mediated hydroxylation and VHL-mediated ubiquitinylation (3, 15) . (ii) Factor inhibiting HIF-1 (FIH) hydroxylates HIF-1α on Asp 803, leading to blockages of the recruitment of the p300/CBP co-activator and subsequent transcription inactivation (16, 17) . (iii) HIF-1α functions as a transcription factor in a heterodimeric form composed of two subunits, HIF-1α and HIF-1β (18) . (iv) HIF-1α protein expression depends on both cap-and IRES-directed translation (19, 20) . (v) Interferon-tau (IFN-τ), one of the Type I IFN produced only in ruminants and/or progesterone regulate HIF mRNA expression in the ovine endometrium and sheep conceptuses (21, 22) . Cytokines and growth factors could stimulate HIF-1α protein synthesis and that cytokines induce the NF-κB-dependent expression of HIF-1α mRNA under hypoxia (23).
Similar to the role of HIF-1α in the hypoxia pathway, IFN functions in immune and inflammatory responses via inducing the expression of IFN-stimulated genes (ISGs) (4, 24) . Among the ISGs, there is a group that functions through conjugation of ISG15 with proteins in a process termed ISGylation. Studies addressing ISG15 expression in primary tumor tissues and cell lines have indicated a link between ISG15 and tumorigenesis (7, (25) (26) (27) (28) . Defects in the IFN system (e.g. due to gene mutations) are traits associated with several tumor types and may affect cancer development (29, 30) . Consequently, IFN, either alone or in combination with other anti-cancer drugs, have been used as a therapeutic strategy against malignancies (7, 31) .
ISG15, which is known as ubiquitin cross-reactive protein precursor, is composed of two ubiquitin-like domains (~ 30% homology to ubiquitin) (4) and ISG15 retains the LRLRGG sequence required for its conjugation with proteins thus conferring ISGylation on its substrates in a manner akin to ubiquitinylation (4, 27, 28, 32 (35) . However, the regulatory role of the ISG15 and the ISGylation system remains to be defined.
The importance of hypoxia and inflammation during tumorigenic processes prompted us to investigate the potential physical, functional and genetic interactions among the key components of the above two microenvironments. Here, we examined the interactions between the interferon-induced inflammatory response and the hypoxia pathway. IFN treatment modulated the levels of free HIF-1α expression. Unexpectedly, HIF-1α not only interacts physically with ISG15 but is also an ISGylation substrate. Further studies determined that ectopic ISG15 expression disrupts the formation of HIF-1α and HIF-1β
heterodimer. Functional studies revealed that ISGylation of HIF-1α compromises the HIF-1α-induced gene expression as well as tumorigenic growth in both soft-agar plates and xenograft mouse models.
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Materials and Methods

Chemicals, plasmids, antibodies and cell culture
All chemicals and the pFLAG-CMV2 plasmid were purchased from Sigma unless otherwise indicated. The pHis-ISG15 plasmid expressing His-tagged ISG15 was a generous gift from Dr. SM Shih (Academia Sinica, Taiwan), and the plasmid expressing the ISG15 G  A mutant was constructed from pHis-ISG15 via site-directed mutagenesis.
ISG15 (amplified by PCR) was cloned into pFlag-CMV2 (Sigma) to generate pFlag-ISG15. The reporter plasmid pXP2-Twist-HRE, control reporter pRL-tk and the pSUPER-based plasmid expressing sh-HIF-1α were generous gifts from Dr. KJ Wu (YMU, Taiwan). The Ube1L-, UbcH8-and HA-Herc5-expressing plasmids came from Dr. RM Krug (U. Texas, USA). The plasmids including pHA-HIF1α-DM, phISG15 and pBabe-HA-VHL were obtained from Addgene. Two plasmids, pHA-HIF-1α and pHA-HIF-1α ΔODD, were provided by Dr. Huang LE (U. Utah, USA). The plasmid pEBB-HIF-1β came from Dr. E. Burstein (U. Texas Southwestern, USA). Fragments of HIF-1α (D1, D2, bHLH, bHLH-PASA, PASA-PASB, PASB, ODD, D2O, D2F1, F1 and F2) were generated via PCR and cloned into the pcDNA3.0-HA vector to generate plasmids expressing the HIF-1α truncated mutants. GST-ISG15, GST-ISG15-N and GST-ISG15-C were constructed via PCR and cloned into pGEX4T-1 (GE Healthcare) for expression. The HA-ubiquitin-expressing plasmid was obtained from Dr. C. Sasakawa (U.
Tokyo, Japan). Polyclonal ISG15 antibodies were raised against recombinant ISG15 proteins and were generated by LTK Biolaboratories, Taiwan. Antibodies against HIF-1α, HIF-1β (BD Bioscience), Flag M2, His, Fibronectin, Vimentin, tubulin, actin (Sigma), HA (Covance), Glut1 (Genetex) and Slug (Anaspec) were obtained commercially. The human 769-P, Caki-1 and 293T renal carcinoma cell lines were obtained from ATCC and were cultivated in DMEM media supplemented with 10% fetal bovine serum, penicillin (100 units/ml), streptomycin (100 µg/ml) and glutamine (2 mM) at 37 °C in an incubator with 21% O 2 and 5% CO 2 , to provide normoxic conditions. Hypoxic treatment was performed by harvesting cells in a hypoxia incubator (ASTEC) with 5% CO 2 , 1% O 2 , and 94% N 2 . Simulated hypoxia was achieved by exposure to 260 μM DFX or 200-500 μM CoCl 2 .
RNA interference
Plasmids expressing shRNA sequences targeting sh-ISG15 and sh-Luc came from the National RNAi Core Facility (http://rnai.genmed.sinica.edu.tw), Taiwan. The targeted sequences were as the followings: sh1-ISG15, 5'-GTGGTGGACAAATGCGACGAA-3'; sh2-ISG15, 5'-CATGTCGGTGTCAGAGCTGAA-3' and sh-luciferase (sh-Luc),
The immunoblotting (IB) and co-immunoprecipitation analyses
Cells were seeded into 6-cm dishes at a density of 0. SDS-PAGE, followed by IB analysis (36) .
Pull-down assays
GST pull-down assays: Briefly, 20 μl of GST-Sepharose beads was incubated with GST or GST-ISG15 fusion proteins in a final volume of 300 μl of sonication buffer (50 mM Na 2 H 2 PO 4 pH 8.0, 300 mM NaCl, 20% glycerol, 1 mM DTT and 1 mM PMSF) at 4 °C for 1 hour with rotation. The beads were washed 5 times with 0.8 ml of sonication buffer containing 1% Triton X-100 and once with 0.8 ml of co-immunoprecipitation buffer supplemented with a 1X protease inhibitor cocktail, 1 mM DTT and 1 mM PMSF. The beads were reacted with a 300 μl mixture containing the IVTT lysates, BSA (2 mg/ml), 1X protease inhibitor cocktail, 1 mM DTT and 1 mM PMSF at 4 °C for 1 hour with rotation, washed 3 times with co-immunoprecipitation buffer, boiled for 7 min in 1X SDS sample buffer, and then subjected to IB analysis (37) .
Ni-NTA pull-down assays: 293T cells were transfected with the His-ISG15-, Ube1L-, UbcH8-, and HA-HERC5-expressing plasmids (the ISGylation system) using polyject (SignaGen) or lipofectamine 2000 (Invitrogen). After the various treatments, the cells were lysed in lysis buffer B (1% NP40, 20mM Imidazole, 10 mM NEM, 1mM Na 3 VO 4 , and 1X protease inhibitor cocktail in 1X PBS buffer). After the addition of 40 μl of Ni-NTA agarose (Qiagen), the mixtures were incubated at 4 °C for 3 hours. The pull-down products were washed 4 times with lysis buffer B supplemented with 5mM was determined by trypan blue exclusion assay.
Anchorage-independent growth on soft agar: Cells (4 x 10 4 , 769-P; 5 x 10 3 , Caki-1) were mixed with 2 ml of 0.3% agarose (Genetex)-containing DMEM medium and overlaid on a pre-coated layer of 0.6% agarose DMEM (2 ml) in 6-well plates. After incubation for 3-4 weeks, the colonies were stained using 0.02% crystal violet, and the number of colonies was scored. 
Tumor formation in NOD-
Quantitative measurements and statistical analyses
Quantitative measurements of the obtained results were performed using ImageQuant program following the manufacturer's protocol (Molecular Dynamics) and presented as the mean + standard error of mean (S.E.M.) of three independent experiments (n = 3).
Statistical analyses were performed using the simple Student's t-test. The data were considered to be significant if the P value was less than 0.05 (P < 0.05).
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ISG15 reduces HIF-1α expression
Because ISG15 reduces the overall ubiquitinylate levels and the camptothecin-induced downregulation of topoisomerase I (TOP1) (35) and the UPP plays a main role in HIF-1α stability and TOP1 downregulation of topoisomerases, we examined the impact of ISG15 on the DFX-and CoCl 2 -induced accumulation of HIF-1α proteins. As shown, ISG15 expression reduced the levels of free HIF-1α in 293T cells (Fig. 1B) . Similar results were also observed in both Caki-1 and 769-P cells (Figs. 1C) . Gene dosage-dependence of the ISG15-mediated reduction of HIF-1α level was also observed (Fig. 1D ).
Next, we determined the molecular mechanism(s) underlying the ISG15-mediated reduction of free HIF-1α level. Because this reduction was detected in VHL-deficient 769-P cells, the VHL-dependent UPP is likely not involved. Moreover, ISG15 could still reduce the levels of free HIF-1α in 769-P cells in which the proteasome was inhibited by MG-132 (Fig. 1E ). In Fig. 1F , we showed that ISG15 expression only minimally affected HIF-1α mRNA expression suggesting a transcription-independent reduction. Together, our results suggest that ISG15 reduces the protein level of free HIF-1α. This notion is further supported by that 769-P sh-ISG15 cells exhibit a higher HIF-1α level than the control sh-Luc cells (Fig. 1G) . Interestingly, the reduction of HIF-1α levels by ISG15 was detected in the immunoblotting assay (to detect free HIF-1α), but not seen in a dot-blotting assay (to detect overall HIF-1α) (Fig.1H) . Similar results were obtained in 293T cells treated with IFN (Fig. S2G) . These findings thus suggested that the reduction of free HIF-1α levels caused by ISG15 expression or IFN treatment might be due to an increase in post-translational modifications (PTMs, possibly ISGylation) of HIF-1α, then leading to mobility change and reduction of free HIF-1α level.
ISG15 interacts with HIF-1α
To examine interaction(s) between HIF-1α and ISG15 proteins, co-immunoprecipitation experiments were performed. We showed that HIF-1α interacts physically with ISG15 under hypoxia treatments ( Fig. 2A) . Similarly, when 293T cells were transfected with plasmids expressing Flag-tagged ISG15 and HA-tagged HIF-1α, anti-Flag antibodies were able to effectively precipitate both ISG15 and HIF-1α from extracts of cells treated with DFX (Fig. 2B) or CoCl 2 ( Supplementary Fig. S3A ). Ectopically expressed HIF-1α also co-localized with ISG15 in cells exposed to IFN and DFX (Fig. S3B) .
We generated HIF-1α C'-(D1) and N'-truncated (D2) mutants and demonstrated that the ISG15-interacting domain is located within the N'-terminus of HIF-1α (Fig. 2C) . A similar conclusion was also obtained via GST pull-down (PD) assay using recombinant proteins obtained from bacterially expressed GST-tagged ISG15 fragments and HA-fused HIF-1α mutant proteins produced in rabbit reticulocyte lysates (Fig. 2D) . We mapped the ISG-interacting domain within the PASB domain of HIF-1α (Fig. S3C) . Differing from full-length ISG15, the N'-or C'-terminus of ISG15 alone cannot interact with full-length HIF-1α (Fig. 2E) , HIF-1α ΔODD and D1 fragments (Fig. S3D ).
HIF-1α is an ISGylation substrate
Research. HIF-1α hydroxylation (at P402/564) allows recognition and ubiquitination by the VHL E3 ligase (15) . Next, a DM plasmid containing HIF-1α mutated at two hydroxylation sites (P402/564A) was transfected into cells. HIF-1α DM resulted in a higher overall level of HIF-1α and HIF-1α was similarly ISGylated (Fig. 3E) . HIF-1α ISGylation also occurred in VHL-deficient 769-P cells and complementation with functional VHL did not affect HIF-1α ISGylation (Fig. 3F) . In sum, we suggest that the ISGylation of HIF-1α plays a role in reducing the free HIF-1α levels upon cellular exposure to IFN and the ISGylation of HIF-1α is distinct from the ubiquitinylation of HIF-1α.
Plasmids expressing different HIF-1α deletion mutants were co-transfected with a set of plasmids expressing the ISGylation system, followed by pull-down-immunoblotting assays to determine the potential ISGylated domain(s) of HIF-1α. We showed that the ISGylation system caused mobility shifts of HIF-1α ΔODD, D1 and D2 fragments (Fig.   3G ). Different HIF-1α mutants containing specific domains were constructed and used to map the ISGylation sites in HIF-1α (Fig. S4D ). Corresponding domains of these different HIF-1α mutants and ISGylation results are illustrated and summarized in Fig. 3H . Thus, our results suggest that HIF-1α is ISGylated at multiple lysine residues.
Functional interactions of HIF-1α and ISG15
Next, we sought to determine the impact of ISG15 and ISGylation on the activity of HIF-1α as a transcription factor. We performed luciferase reporter experiments using a Twist promoter construct (pTwist-Luc) containing hypoxia-responsive elements (HREs) (39) . Ectopic expression of ISG15 decreased HIF-1α-driven luciferase expression (Fig.   4A ). In addition to hypoxia-targeting genes (e.g., Glut1), HIF-1α is known to regulate expression of genes involved in the epithelial-mesenchymal transition (EMT, e.g., vimentin) (4). In Fig. 4B , expression of the ISGylation system in 293T cells caused a reduction in the VIM mRNA expression. A similar reduction in the HIF-1α-mediated vimentin protein expression by the ISGylation system was observed under normoxia or DFX treatment (Fig. 4C) . These above data suggest that ISG15 and the ISGylation system compromise HIF-1α transcriptional activity.
Functional expression of HIF-1α caused elevated expression of EMT markers, such as vimentin, fibronection, Glut1 and Slug, depending on the cell lines involved (Figs. 4D- 1 and 2) . Expression of the ISGylation system reduced the levels of EMT proteins in 293T cells (Fig. 4D , compare lane 2 to lanes 3 and 4) and 769-P cells (Fig. 4E,   compare lanes 2 and 3) . We further knocked down ISG15 expression in 769-P cells and the expression levels of EMT markers including vimentin, Glut1 and fibronectin were found to be significantly higher in 769-P sh-ISG15 cells than sh-Luc cells (Fig. 4F) .
Similarly, IFN treatment also reduced the hypoxia-induced expression of vimentin and Glut1 (Fig. 4G) . Together, our results showed that both hypoxia and IFN stimulate the ISGylation system and that interactions of ISG15 with HIF-1α reduce the transcriptional activity of HIF-1α.
ISG15 and ISGylation negatively regulate HIF-1α-mediated gene expression: underlying mechanisms
We studied the potential mechanism(s) underlying the ISG15-and ISGylation-mediated reduction of HIF-1α activity. Co-immunoprecipitation experiments showed that ISG15 disrupted HIF-1α/HIF-1β dimerization (Fig. 5A) . Unexpectedly, our results revealed that ISG15 expression, like VHL expression, promoted HIF-1α ubiquitinylation (Fig. 5B ).
Under inhibition of protein synthesis, the expression or knockdown of ISG15 shortened (from ~ 50 to ~ 15 min) or lengthened (from ~ 50 to ~ 90 min) the half-lives of HIF-1α (t 1/2 ), respectively ( Fig. 5C and data not shown) . In Fig. 5D , dot-blotting analyses revealed that the overall levels of HIF-1α were reduced with expression of the ISGylation system. Notably, the ISG15 conjugation ability plays a role in that it reduces free HIF-1α level, because the conjugation-defective ISG15 G  A mutant has no effect on free HIF-1α levels (Fig. 5E ). Proteasome inhibitors (MG-132 and lactacystin) both restored HIF-1α level (Fig. 5F ) and the expression of ISGylation efficiently reduced the expression of 
HIF-1α DM (Fig. 5G) . The accumulation of HIF-1α due to DFX treatment appears to be slowed down in cells with ISG15 expressed (data not shown). In sum, our data suggest that ISG15 and/or ISGylation regulate HIF-1α-mediated gene expression via the following mechanisms: (i) prevention of the dimerization of HIF-1α with HIF-1β; (ii) promotion of the ubiquitinylation of HIF-1α; and (iii) accelerated degradation of HIF-1α.
Biological impacts of ISG15 on HIF-1α-mediated cellular proliferation and tumorigenesis
HIF-1α regulates the expression of more than 100 genes encoding proteins that function in various biological processes such as tumorigenesis (4). We next determined the effect of ISG15 expression on tumor growth. ISG15 expression reduced clonogenic growth (Fig.   6A ) and cellular proliferation (Fig. 6B ) of cells. Importantly, ISG15 expression in 769-P and Caki-1 not only reduced anchorage-independent growth but also tumor growth in a mouse xenograft model (Figs. 6C-D) . We confirmed the elevated levels of ISG15 and/or ISGylates in tumor samples extracted from mice (Fig. 6E) . Consistently, HIF-1α ΔODD expression promoted anchorage-independent growth ability in Caki-1 cells (~ 2.4-fold) and this HIF-1α-promoted tumorigenic growth ability was abolished by ISG15 expression (Fig. 7F ). In conclusion, our results provide the first experimental evidence that ISG15 and ISGylation reduce transcription activity of HIF-1α and subsequently affect HIF-1α-mediated biological functions, such as EMT and tumorigenic growth. The ISGylation of RIG-I reduced both basal and virus-induced IFN promoter activity (49) . We found that ISG15 is able to be conjugated to HIF-1α then leading to reductions in both the cellular level of the free-form HIF-1α and the HIF-1α function. We have further determined that ISG15 conjugates with multiple domains on HIF-1α. However, we were unable to map the lysine residues within HIF-1α that are involved in ISGylation. ISG15 also caused a reduction of the ectopically expressed level of free HIF-1α, but not the overall level of HIF-1α. At 24 hours post-transfection, the cells were lysed and the lysates were subjected to IB (right panel, for free HIF-1α) and dot blotting assays (left panel, for overall HIF-1α levels). *, P < 0.05; **, P < 0.01; ***, P < 0.001; NS, not 
